IODP Expeditions 309 and 312 drill an intact section of upper oceanic basement into gabbros

The Integrated Ocean Drilling Program's (IODP) Expeditions 309 and 312 successfully completed the first sampling of an intact section of upper oceanic crust, through lavas and the sheeted dikes into the uppermost gabbros. Hole 1256D, which was initiated on the Ocean Drilling Program's (ODP) Leg 206, now penetrates to >1500 mbsf and >1250 m sub-basement. The first gabbroic rocks were encountered at 1407 mbsf. Below this, the hole penetrates 3c100 m into a complex zone of fractionated gabbros intruded into contact metamorphosed dikes

Zircon U-Pb Geochronology Constrains Continental Expression of Great Meteor Hotspot Magmatism

The New England-Québec Igneous Province is considered to be a continental expression of Great Meteor Hotspot magmatism, though other geodynamic scenarios have been suggested. Existing geochronologic data lack the needed accuracy and precision to permit tests of potential causal mechanisms. We provide zircon U-Pb ages for four igneous centers and a suite of plate reconstructions and show that the duration between magmatism in each branch of this province is ca. 3–6 Myr shorter and ca. 10 Myr older than predicted if the spatial-temporal distribution of magmatism conformed to a well-defined age progression. However, in addition to uncertainties in plate reconstructions, variable regional crustal thickness or lithospheric topography likely played a role in mediating the rates of melt transport to emplacement depth and we therefore cannot reject the hotspot hypothesis. Our results place the best-available chronological constraints on continental magmatism associated with one of the oldest and longest-lived hotspots. © 2021. American Geophysical Union. All Rights Reserved.6 month embargo; published online: 05 June 2021This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas.

Histopathology KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas Aims:  To determine whether KRAS mutations occur in primary bladder adenocarcinoma. Methods and results:  Twenty-six cases of primary urinary bladder adenocarcinoma were analysed. DNA was extracted from formalin-fixed, paraffin-embedded tissue and amplified with shifted termination assay technology, which recognizes wild-type or mutant target sequences and selectively extends detection primers with labelled nucleotides. A mutation in KRAS was found in three (11.5%) of 26 primary bladder adenocarcinomas. Two of these three cases exhibited a G13D mutation, whereas the remaining case contained a mutation in G12V. None of the ten cases of urothelial carcinoma with glandular differentiation displayed KRAS mutation. Colonic adenocarcinoma contained a KRAS mutation in 18 (33%) of 55 cases. There was no distinct difference with regard to grade, stage or outcome according to the limited clinicopathological data available. However, the two youngest patients, aged 32 and 39 years, in our study group, with a mean population age of 61 years, were found to have mutations in KRAS. Conclusions:  KRAS mutations are present in a small subset of primary urinary bladder adenocarcinomas. Future clinical trials for treatment of bladder adenocarcinoma, employing targeted therapies similar to those used for treatment of colon cancer, may also benefit from the predictive implications of KRAS mutational testing

Clinical effectiveness and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins:results from the comparison of LAser, Surgery and foam Sclerotherapy (CLASS) randomised controlled trial

Primary outcome measures: Disease-specific [Aberdeen Varicose Vein Questionnaire (AVVQ)] and generic [European Quality of Life-5 Dimensions (EQ-5D), Short Form questionnaire-36 items (SF-36) physical and mental component scores] quality of life (QoL) at 6 months. Cost-effectiveness as cost per quality-adjusted life-year (QALY) gained. Secondary outcome measures: Quality of life at 6 weeks; residual varicose veins; Venous Clinical Severity Score (VCSS); complication rates; return to normal activity; truncal vein ablation rates; and costs. Results: The results appear generalisable in that participants’ baseline characteristics (apart from a lower-than-expected proportion of females) and post-treatment improvement in outcomes were comparable with those in other RCTs. The health gain achieved in the AVVQ with foam was significantly lower than with surgery at 6 months [effect size -1.74, 95% confidence interval (CI) -2.97 to -0.50; p = 0.006], but was similar to that achieved with EVLA. The health gain in SF-36 mental component score for foam was worse than that for EVLA (effect size 1.54, 95% CI 0.01 to 3.06; p = 0.048) but similar to that for surgery. There were no differences in EQ-5D or SF-36 component scores in the surgery versus foam or surgery versus EVLA comparisons at 6 months. The trial-based cost-effectiveness analysis showed that, at 6 months, foam had the highest probability of being considered cost-effective at a ceiling willingness-to-pay ratio of £20,000 per QALY. EVLA was found to cost £26,107 per QALY gained versus foam, and was less costly and generated slightly more QALYs than surgery. Markov modelling using trial costs and the limited recurrence data available suggested that, at 5 years, EVLA had the highest probability (≈ 79%) of being cost-effective at conventional thresholds, followed by foam (≈ 17%) and surgery (≈5%). With regard to secondary outcomes, health gains at 6 weeks (